International Journal of Hematology

, Volume 107, Issue 4, pp 478–485 | Cite as

Long-term outcome in patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation

  • Olle Ringdén
  • Behnam Sadeghi
  • Gianluca Moretti
  • Sigrun Finnbogadottir
  • Brita Eriksson
  • Jonas Mattsson
  • Britt-Marie Svahn
  • Mats Remberger
Original Article


Patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT) were given the option to be treated at home during the pancytopenic phase. Daily visits by a nurse and phone calls from a physician from the unit were part of the protocol. During almost two decades, 252 patients with haematological malignancies and non-malignant disorders were included. Median age was 47 (range 0–72) years. Myeloablative conditioning was given to 102 patients and reduced intensity to 150. Donors were matched unrelated (n = 160), HLA-identical siblings (n = 71), or HLA-mismatched (n = 21). Cumulative incidence of acute graft-versus-host disease (GVHD) was 35% and that of chronic GVHD was 46%. Non-relapse mortality was 14% 10 years after HSCT. In patients with haematological malignancies (n = 229), the 10-year probability of relapse was 34%. No patients died at home. Overall survival was 59% and relapse-free survival was 50% after 10 years. We conclude that patients treated at home after HSCT have an encouraging long-term outcome.


Allogeneic hematopoietic stem cell transplantation Home care Neutropenia Graft-versus-host disease 



We thank Inger Holmström and Gunilla Tillinger for excellent preparation of this manuscript. This study was supported by grants from the Swedish Cancer Society (CAN2013/671), the Swedish Research Council (K2014-64X-05971-34-4), the Children’s Cancer Foundation (PR2013-0045), the Cancer Society in Stockholm (111293), and Karolinska Institutet.

Compliance with ethical standards


The authors have no disclosure.


  1. 1.
    Hoogerbrugge PM, Brouwer OF, Bordigoni P, Ringden O, Kapaun P, Ortega JJ, et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet. 1995;345(8962):1398–402.CrossRefPubMedGoogle Scholar
  2. 2.
    Storb R, Prentice RL, Thomas ED, Appelbaum FR, Deeg HJ, Doney K, et al. Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anaemia. Br J Haematol. 1983;55(4):573–85.CrossRefPubMedGoogle Scholar
  3. 3.
    Thomas ED, Buckner CD, Banaji M, Clift RA, Fefer A, Flournoy N, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977;49(4):511–33.PubMedGoogle Scholar
  4. 4.
    Buckner CD, Clift RA, Sanders JE, Meyers JD, Counts GW, Farewell VT, et al. Protective environment for marrow transplant recipients: a prospective study. Ann Intern Med. 1978;89(6):893–901.CrossRefPubMedGoogle Scholar
  5. 5.
    Passweg JR, Rowlings PA, Atkinson KA, Barrett AJ, Gale RP, Gratwohl A, et al. Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant. 1998;21(12):1231–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Skinhoj P, Jacobsen N, Hoiby N, Faber V. Strict protective isolation in allogenic bone marrow transplantation: effect on infectious complications, fever and graft versus host disease. Scand J Infect Dis. 1987;19(1):91–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Svahn BM, Bjurman B, Myrback KE, Aschan J, Ringden O. Is it safe to treat allogeneic stem cell transplant recipients at home during the pancytopenic phase? A pilot trial. Bone Marrow Transplant. 2000;26(10):1057–60.CrossRefPubMedGoogle Scholar
  8. 8.
    Svahn BM, Remberger M, Myrback KE, Holmberg K, Eriksson B, Hentschke P, et al. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood. 2002;100(13):4317–24.CrossRefPubMedGoogle Scholar
  9. 9.
    Russell JA, Poon MC, Jones AR, Woodman RC, Ruether BA. Allogeneic bone-marrow transplantation without protective isolation in adults with malignant disease. Lancet. 1992;339(8784):38–40.CrossRefPubMedGoogle Scholar
  10. 10.
    Ringden O, Karlsson H, Olsson R, Omazic B, Uhlin M. The allogeneic graft-versus-cancer effect. Br J Haematol. 2009;147(5):614–33.CrossRefPubMedGoogle Scholar
  11. 11.
    Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300(19):1068–73.CrossRefPubMedGoogle Scholar
  12. 12.
    Svahn BM, Ringden O, Remberger M. Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;36(6):511–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Ringden O, Remberger M, Torlen J, Engstrom M, Fjaertoft G, Mattsson J, et al. Home care during neutropenia after allogeneic hematopoietic stem cell transplantation in children and adolescents is safe and may be more advantageous than isolation in hospital. Pediatr Transplant. 2014;18(4):398–404.CrossRefPubMedGoogle Scholar
  14. 14.
    Ringden O, Remberger M, Holmberg K, Edeskog C, Wikstrom M, Eriksson B, et al. Many days at home during neutropenia after allogeneic hematopoietic stem cell transplantation correlates with low incidence of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2013;19(2):314–20.CrossRefPubMedGoogle Scholar
  15. 15.
    Omazic B, Remberger M, Barkholt L, Soderdahl G, Potacova Z, Wersall P, et al. Long-Term follow-up of allogeneic hematopoietic stem cell transplantation for solid cancer. Biol Blood Marrow Transplant. 2016;22(4):676–81.CrossRefPubMedGoogle Scholar
  16. 16.
    Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelov L, et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood. 1994;83(9):2723–30.PubMedGoogle Scholar
  17. 17.
    Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91(3):756–63.PubMedGoogle Scholar
  18. 18.
    Beelen DW, Haralambie E, Brandt H, Linzenmeier G, Muller KD, Quabeck K, et al. Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation. Blood. 1992;80(10):2668–76.PubMedGoogle Scholar
  19. 19.
    Ringden O, Remberger M, Persson U, Ljungman P, Aldener A, Andstrom E, et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant. 1995;15(4):619–25.PubMedGoogle Scholar
  20. 20.
    Forslow U, Blennow O, LeBlanc K, Ringden O, Gustafsson B, Mattsson J, et al. Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation. Eur J Haematol. 2012;89(3):220–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Schaffer M, Aldener-Cannava A, Remberger M, Ringden O, Olerup O. Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. Tissue Antigens. 2003;62(3):243–50.CrossRefPubMedGoogle Scholar
  22. 22.
    Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Loffler H, et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood. 1995;85(6):1666–72.PubMedGoogle Scholar
  23. 23.
    Ringden O, Remberger M, Runde V, Bornhauser M, Blau IW, Basara N, et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood. 1999;94(2):455–64.PubMedGoogle Scholar
  24. 24.
    Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood. 1989;73(6):1729–34.PubMedGoogle Scholar
  25. 25.
    Torlen J, Ringden O, Garming-Legert K, Ljungman P, Winiarski J, Remes K, et al. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation. Haematologica. 2016;101(11):1417–25.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with post transplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033–40.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–50.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295–304.CrossRefPubMedGoogle Scholar
  29. 29.
    Carlens S, Ringden O, Remberger M, Lonnqvist B, Hagglund H, Klaesson S, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant. 1998;22(8):755–61.CrossRefPubMedGoogle Scholar
  30. 30.
    Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100(2):406–14.CrossRefPubMedGoogle Scholar
  31. 31.
    Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 1995;86(7):2815–20.PubMedGoogle Scholar
  32. 32.
    De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–21.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRefGoogle Scholar
  34. 34.
    Jones JM, Wilson R, Bealmear PM. Mortality and gross pathology of secondary disease in germfree mouse radiation chimeras. Radiat Res. 1971;45(3):577–88.CrossRefPubMedGoogle Scholar
  35. 35.
    van Bekkum DW, Roodenburg J, Heidt PJ, van der Waaij D. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst. 1974;52(2):401–4.CrossRefPubMedGoogle Scholar
  36. 36.
    Storb R, Prentice RL, Buckner CD, Clift RA, Appelbaum F, Deeg J, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med. 1983;308(6):302–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Bostrom L, Ringden O, Sundberg B, Linde A, Tollemar J, Nilsson B. Pretransplant herpesvirus serology and acute graft-versus-host disease. Transplantation. 1988;46(4):548–52.CrossRefPubMedGoogle Scholar
  38. 38.
    Gratama JW, Zwaan FE, Stijnen T, Weijers TF, Weiland HT, D’Amaro J, et al. Herpes-virus immunity and acute graft-versus-host disease. Lancet. 1987;1(8531):471–4.CrossRefPubMedGoogle Scholar
  39. 39.
    Reddy P, Ferrara JL. Immunobiology of acute graft-versus-host disease. Blood Rev. 2003;17(4):187–94.CrossRefPubMedGoogle Scholar
  40. 40.
    Fondell E, Axelsson J, Franck K, Ploner A, Lekander M, Balter K, et al. Short natural sleep is associated with higher T cell and lower NK cell activities. Brain Behav Immun. 2011;25(7):1367–75.CrossRefPubMedGoogle Scholar
  41. 41.
    Svahn BM, Remberger M, Heijbel M, Martell E, Wikstrom M, Eriksson B, et al. Case-control comparison of at-home and hospital care for allogeneic hematopoietic stem-cell transplantation: the role of oral nutrition. Transplantation. 2008;85(7):1000–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Hebart H, Klingspor L, Klingebiel T, Loeffler J, Tollemar J, Ljungman P, et al. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. Bone Marrow Transplant. 2009;43(7):553–61.CrossRefPubMedGoogle Scholar
  43. 43.
    Svahn BM, Alvin O, Ringden O, Gardulf A, Remberger M. Costs of allogeneic hematopoietic stem cell transplantation. Transplantation. 2006;82(2):147–53.CrossRefPubMedGoogle Scholar
  44. 44.
    Sive J, Ardeshna KM, Cheesman S, le Grange F, Morris S, Nicholas C, et al. Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experience. Leuk Lymphoma. 2012;53(12):2397–404.CrossRefPubMedGoogle Scholar
  45. 45.
    Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. New Engl J Med. 2010;363(22):2091–101.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Remberger M, Ackefors M, Berglund S, Blennow O, Dahllof G, Dlugosz A, et al. Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2011;17(11):1688–97.CrossRefGoogle Scholar
  47. 47.
    Horan JT, Logan BR, Agovi-Johnson MA, Lazarus HM, Bacigalupo AA, Ballen KK, et al. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? J Clin Oncol. 2011;29(7):805–13.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  1. 1.Department of LABMED, Translational Cell Therapy Research Group (TCR)Karolinska Institutet, Kliniskt Forskningscentrum (KFC)HuddingeSweden
  2. 2.Department of Oncology-PathologyKarolinska InstitutetHuddingeSweden
  3. 3.Centre for Allogeneic Stem Cell TransplantationKarolinska University Hospital HuddingeStockholmSweden

Personalised recommendations